Moderna, Inc. (MRNA) 今日盘前股价大幅上涨5.78%，引起了市场的广泛关注。
消息面上，此次上涨主要受到多重利好消息的推动。首先，公司近日公布了其mRNA汉坦病毒疫苗的一期临床试验积极数据，该疫苗耐受性良好，并在所有剂量组中均诱导出了强劲的抗体反应，这验证了其mRNA技术平台应对多种病毒疾病的能力。
其次，公司公布的第一季度财务表现强劲，营收达到3.89亿美元，远超分析师普遍预期的2.28亿美元，主要得益于国际新冠疫苗销量的强劲增长。此外，其在研的mRNA个性化肿瘤治疗性疫苗EVM16的首次人体试验数据也表现积极。基于这些积极的研发进展和超预期的财务业绩，瑞银（UBS）上调了对该公司的目标价。这些因素共同增强了市场对Moderna技术领先地位及未来增长潜力的信心，从而推动了股价在盘前走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.